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Discussion
Dr Wilson Szeto (Philadelphia, Pa). I congratulate you on a
well-done study. My disclosure is that I am an investigator in the
PARTNER trial at our institution at the University of Pennsylvania.
This presentation is a timely and important topic. We have all
struggled with the question of futility versus utility in these pa-
tients. The so-called eyeball test is what you are referring to; how
do we determine which patients are ‘‘too sick’’ for even TAVR?
I applaud you and agree with you in your multivariate analysis
that we have now learned that factors such as end points in VARC-
2 and mild paravalvular leak may have a late impact on outcome. I
applaud you for an in-depth analysis eliminating those factors
when you examine your multivariate analysis predictors of death.
One of the issues that we have struggled with over the last few
years in terms of determining what is considered futile is this
whole question of an ‘‘eyeball test’’ and noncardiac factors that
are not captured in the Society of Thoracic Surgeons predicted
risk of mortality, such as frailty, dementia, cirrhosis. Do you
have any information to share with us regarding these factors in
your patient cohort, and what impact do you think there would
have been on your analysis?
Dr D’Onofrio.We don’t have data about frailty in this registry.
Frailty is difficult to quantify, especially in patients undergoing
cardiac surgery, because there are no specific scores for them.The Journal of Thoracic and CaThere are so many different scores, and these evaluations are
subjective. I cannot answer this question because I don’t have
data on frailty, but it would be interesting to analyze this aspect.
Regarding cirrhosis, we had only 4 patients in this population
(2 in group F and 2 in group NF), and these numbers are too small
to evaluate the impact of this variable on postoperative outcomes.
We believe that dementia is a contraindication to a transcatheter
aortic valve implantation, because it would not improve quality of
life or patient survival. We don’t usually perform TAVI in patients
with dementia.
Dr Szeto.Another important outcome that we have all looked at
in TAVR is the question of functional recovery and quality of life.
Do you have any data to share with us regarding the 2 groups, the F
andNF groups?Were there any differences in thosemetrics in your
study?
DrD’Onofrio. It is difficult to compare these groups in terms of
functional recovery, because the group ‘‘F’’ has a short follow-up.
By looking at the data, we observed that 40% of patients in group
F, futile patients, died of cardiovascular causes. So I suppose the
functional recovery is worse in these patients. But it is difficult
to compare the 2 groups, because these patients have only 6
months follow-up, and the other patients have 4 to 5 years
follow-up.
It would be interesting to analyze these patients in terms of
quality of life, because this is another important aspect of futility.
Unfortunately, we don’t have data on quality of life. It would be
interesting to analyze futility not only in terms of survival but
also in terms of quality of life. So if somebody in the audience
has these data and would like to share it with us, we could extend
this study and maybe present it next year.
Dr Szeto. From a practical standpoint in terms of how you
evaluate patients in your valve clinic, on the basis of your data,
what would you recommend to the rest of us as we try to better
sort out which patients are futile and which patients we should
treat? What would you recommend at this point? You alluded to
it a bit at the end of your presentation.
Dr D’Onofrio. If we honestly believe that a patient would not
improve quality of life or survival with a TAVI, we have to deny
TAVR to that patient. It is crucial to comprehensively counsel
patients and their families. We don’t think that all patients with
these predictors of futility should be excluded tout court from
this procedure. There are, as I showed in the slides, a lot of patients
who, despite chronic kidney disease and with rhythm disorders
that are predictors of futility, had a good outcome after the
procedure. So it is not a good reason to exclude these patients
only because they have these risk factors. Good counseling and
more attention to their procedure and immediate postoperative
period are recommended.
Dr Harold Lazar (Boston, Mass). What type of patients would
you say no to on the basis of your study? What type of patients
would you not offer this technique to?
Dr D’Onofrio. It is impossible to identify exactly what kind of
patients we should say no to. We have to evaluate many things,
such as risk factors and general clinical conditions. The ‘‘eyeball
test’’ is important, especially now that we have some good
experience with these patients. Taking into account all these
factors, we should be able to understand which patients are more
likely to have a poor postoperative outcome.rdiovascular Surgery c Volume 148, Number 3 979
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DDr Lazar. So a 75-year-old patient who is intubated, with
congestive heart failure, inotropes, and worsening kidney function,
would you operate on that patient?
Dr D’Onofrio. If the patient is in an acute phase of disease and
the main cause of the condition is aortic valve disease, I would
operate on this patient. I would not operate on a 92-year-old patient
who has chronic kidney disease, poor mobility, and all the other
well-known associated conditions; to me, this makes no sense.
But if, like you said, a 75-year-old patient has acute heart failure,
I would do it, and actually we did it with good results.
Dr A. Pieter Kappetein (Rotterdam, The Netherlands). The ti-
tle of your presentation is great, and listening to your presentation I
thought, ‘‘He is finally going to tell mewhich patients not to treat.’’
But what you tell us is that diabetes, LVEF, high pulmonary
pressure, kidney disease, and conduction disturbances are not
good. So which of those predictive factors were not surprising
and which were new to you?
Dr D’Onofrio. That is a good point. I would have expected
functional class to be an independent predictor of a bad outcome,
and I would have also expected euroSCORE to be a predictor of a
bad outcome. In our previous articles, euroSCORE and functional
class were identified as risk factors for mortality, so I would have
expected that these factors would have been significant in these
patients also.
Dr Kappetein. This is important, because you can teach us
which variables we should not take into account, for example,
euroSCORE. Is that what you mean?
Dr D’Onofrio. Correct.
Dr Kappetein. This means that we should not take into account
the euroSCORE. Is that what you mean?980 The Journal of Thoracic and Cardiovascular SurgDr D’Onofrio. It seems that just some of the variables that are
included in the euroSCORE should be taken into account, but not
the euroSCORE itself.
Dr Kappetein. Why do you think the euroSCORE is not
predictive then? What is the reason for that?
Dr D’Onofrio. Probably because it takes into account a lot of
variables that don’t have an impact on these particular patients,
and it is not tailored specifically for these high-risk patients with
aortic disease.
Dr Kappetein. So don’t use the euroSCORE in these types of
patients?
Dr D’Onofrio. Well, use it, but rather look at each single
variable included in the euroSCORE. Furthermore, look at the
patient in all aspects.
Dr Lazar. One final quick question. You have been putting
these in, or the registry has documented these, since 2008?
Dr D’Onofrio. Yes.
Dr Lazar. Can you give us some idea what the freedom from
structural deterioration of these valves are and what percent have
had to be replaced?
Dr D’Onofrio.We just updated this registry, and now we have
approximately 1000 patients. We have approximately 5 years
follow-up with a mean follow-up of approximately 2.5 years,
and we haven’t observed any structural valve deterioration so
far. However, the duration of follow-up is still too short.
Dr Lazar. Paravalvular leaks?
Dr D’Onofrio. Paravalvular leaks are approximately 40%,
including mild, moderate, and severe. In particular, moderate
and severe leaks occurred in approximately 8% of patients, and
they have a significant impact on survival in our registry.ery c September 2014
